NasdaqGS:SRPTBiotechs
Sarepta’s Elevidys Data Reshapes Duchenne Risk Profile For Long-Term Investors
Sarepta Therapeutics reported positive three year Phase 3 EMBARK results for Elevidys in Duchenne muscular dystrophy.
The data show sustained efficacy, a slowdown in disease progression, and no new safety issues in ambulatory patients.
The FDA has updated the Elevidys label to broaden its approved use based on these results.
Sarepta Therapeutics (NasdaqGS:SRPT) is drawing attention after these EMBARK results, especially given its current share price of $20.34. The stock has seen a 1 year...